Cash runway into Q1 2027 is very short for a clinical-stage company; monitor for financing or partnership announcements. VIRAGE2 enrollment completion and initial data in Q3 2027 are the next key catalysts.
Drug in focus
TOVX drug pipeline →VCN-01
▲ Bullish Named in this press release- Impact
- Phase
- Phase 2b completed; Phase 2a (VIRAGE2) authorized/enrolling; Phase 3 design aligned with FDA and EMA
- Time to market
- Likely 4-6 years if Phase 3 is successful, assuming the company secures funding/partnership to initiate a pivotal trial
- Next catalyst
- None dated
What to watchVCN-01 is the only meaningful asset at a ~$10M market-cap company. The positive VIRAGE Phase 2b data and FDA/EMA alignment on Phase 3 design are real positives, but the company has only ~$14M cash (runway into Q1 2027) and needs a partnership or dilutive financing to fund the pivotal trial. Watch for partnership/licensing announcements and VIRAGE2 interim data as the next catalysts, the stock is highly binary and prone to large swings.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $0.1600entry
- T+1 · 4d ago −9.94%α −9.57% · $0.1441
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theriva Biologics reported Q3 2026 net loss of $1.47M ($0.03 per share), narrower than the $4.36M loss a year ago, driven by a 76% drop in R&D spending after completing the VIRAGE Phase 2b trial. Cash of $8.5M provides runway only into Q1 2027, and the company completed the sale of its SYN-004 microbiome assets for $350K upfront plus milestones. The VIRAGE2 trial is expected to complete enrollment in Q4 2026 with initial data by Q3 2027.
Key Financial Metrics
Key Facts
- Q3 2026 net loss $1.47M ($0.03 per share) vs $4.36M ($0.45) in Q3 2025
- Cash and equivalents $8.5M as of Sep 30, 2026, down from $13.1M at Dec 31, 2025
- Cash runway into Q1 2027
- VIRAGE2 Phase 2a enrollment expected to complete Q4 2026, initial data by Q3 2027
- SYN-004 (ribaxamase) and related assets sold to Biossil Labs for $350K upfront plus up to $91M milestones and royalties
- General and administrative expenses fell 51% to $923K; R&D expenses fell 76% to $612K
- Weighted average shares outstanding 45.9M vs 9.7M a year ago, reflecting significant dilution
Financial Impact
Cash burn of $4.6M over nine months; cash runway only into Q1 2027; upfront proceeds from asset sale $350K
Risk Factors
- Cash runway only into Q1 2027, requiring near-term financing or strategic alternative
- Significant dilution from share issuance (shares outstanding rose from 35.7M to 45.9M since Dec 2025)
- No revenue; dependent on clinical trial success and regulatory milestones
- SYN-004 sale milestones are contingent and uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3401493 |
Track record
11 reports on TOVX
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Viewing Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
- Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
- Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
- Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
- Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
- Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers